Zydus Cadila has received final approval from the USFDA to market Lamotrigine Extended-Release Tablets USP in the strengths of 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg.
This medication is indicated for the treatment of certain types of seizures and will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.
The group now has 283 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
